PPT-Human genetics and drug discovery:

the future is now Robert Plenge MD PhD Broad Institute Medical and Population Genetics MPG October 1 2015 The Problem http csddtuftsedu Phase IIIII failures drive high cost of drug development. By Andreas Dr Lorenz M.Mayr Drug Discovery World Summer 2006 Miniaturisation ofassay developmentand screening In recent years we have seen a strong increase in the number of chemicalcompounds and mole an Industrial Process. How are drugs . discovered and developed?. Dr Steve Carney, s.carney@elsevier.com. Managing Editor, . Drug Discovery Today. What’s my background?. First degree in Biochemistry. – . get ready for the show. Weidong Zhang. Pfizer. 1. Outline. Overview of omics technology. Application of omics in drug discovery. Case studies from pre-clinical to phase II/III. 2. 3. Omics provide paramount view of biological cascade. Properties: . Optimizing Pharmacokinetics and Safety During Drug . Discovery. ACS Short Course. Li Di and Edward H. Kerns. Introduction to Drug-Like Properties. Few research compounds will become drugs because they lack sufficient pharmacokinetics (PK) and safety. Distinguished University Professor Lecture. Presented on January 29, 2015 by Paul Erhardt, PhD. UT DUP and Director of the Center for Drug Design and Development (CD3). paul.erhardt@utoledo.edu. 1. Outline. Behavior Genetics: . Predicting Individual Differences. The topics in the text:. genes. twin and adoption studies . temperament and heredity. molecular genetics. heritability. gene/environment interaction. Please Sign Up:. . Name. . Email (. Onyen. is fine, or …). . Are You . ENRolled. ?. Dept. & Advisor (Lab?). . Tentative Title (“????” Is OK). . When:. Next Week, Early, Oct., Nov., Late. Gerald J. Wyckoff. Training modes. Are we training . genomicists. to deal with the right problems?. Are the training modalities we’re using proper?. What questions should we be looking at?. Problems in Drug Discovery. Lectures. . – . 17x2 (Med); . 17x1. (. Stom. ). ;. Seminars. – . 17x3 (Med); . 17x2. (. Stom. ). ;. 3 . concluding . tests. (. tests. + . practical part. ). Final . examination . (. tests. + . linking diseases, drivers, targets and drugs. via multi-omics, clinical, imaging and perturbation data fusion. Nathalie Pochet, Ph.D.. Assistant Professor, Harvard Medical School. Associate Scientist, Brigham and Women’s Hospital. Functional Applications of Human Genetics and Genomics Commissioned by the American Society of Human Genetics Produced by TEConomy Partners, LLC. Report Authors: Simon Tripp and Martin Grueber May 2 Tel. No. 2419677/2419361 e - - mysore.ac.in Fax: 0821 - 2419363/2419301 www.uni - mysore.ac.in UNIVERSITY OF MYSORE Estd. 1916 Vishwavidyanilaya Karyasoudha Crawford Hall, Mysuru - 570 005 N Why do drugs fails?. …now it is efficacy/safety.. It was pharmacokinetics…. Human genetics helps to identify potential drug targets to start drug discovery. Disease. Healthy. The key steps are:. M. 1. Dr. Abd El Raheim Donia. Generally,. . a drug . can be . defined . as a . substance that . induces . a response . within the human . body.. Dr. Abd El Raheim Donia. 2. FDA Definition . of a . Drug.